Survey on the Pharmacy Follow-up of Alli Purchasers

Completed

• Conditions: Overweight
• Interventions: Drug: Orlistat

• Registration Number: NCT01387243
• Lead Sponsor: GlaxoSmithKline

Brief Summary

To assess the feasibility and acceptability of genuine pharmacy follow up of people wishing to lose weight.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-03-29
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Study First Submitted QC: 2011-06-30
• Study First Posted: 2011-07-04
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-25
• Last Update Posted: 2012-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Individuals who have been recognized as being eligible for treatment, who have agreed to pharmacy follow up, and have given their informed consent to take part in the survey.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
60 mg Orlistat	Orlistat	Purchased by consumer

Primary Outcome Measures

Name	Time	Method
Change in Physical activity	baseline to 1 year

Secondary Outcome Measures

Name	Time	Method
Change in dietary behavior	baseline to 1 year
Evaluation of care pathway (e.g., consultation with doctors, use of nutritional information)	baseline to 1 year
Satisfaction with management (i.e., results on weight and treatment comfort)	baseline to 1 year